AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Lunit Targets U.S. Breast Cancer Risk Market After NCCN Guideline Update
Korea Biomedical reports that Lunit is eyeing the U.S. breast cancer risk market after an NCCN guideline update. The shift illustrates how guideline changes can quickly reshape commercial opportunities for AI health technology.
Lunit’s U.S. Breast Cancer Push Shows How Guideline Changes Can Reopen Markets for AI
Korean AI imaging company Lunit is reportedly targeting the U.S. breast cancer risk market after an NCCN guideline update. The move shows how fast-moving clinical guidelines can reshape commercial opportunities for AI vendors. For AI companies, the policy environment is not just a backdrop — it is often the main gatekeeper to adoption.
Breast Cancer Screening Enters a New Phase as AI Risk Tools Move Into Guidelines
Breast cancer screening is shifting from one-size-fits-all imaging toward AI-based risk assessment, according to multiple reports on new NCCN guidance. That marks an important step toward earlier, more personalized screening decisions. The change could broaden access to risk stratification tools at a time when clinicians are looking for better ways to identify women who may benefit from earlier or more intensive screening.
NCCN Update Signals Breast AI Is Moving From Novelty to Standard Workflow
NCCN’s latest breast cancer screening guidance appears to formalize a role for AI in screening decisions, reinforcing the momentum around AI-assisted risk assessment. The shift is notable because it comes from a trusted guideline body rather than a vendor or startup. For hospitals and imaging groups, the message is clear: AI is increasingly expected to support clinical decision-making, not just demonstrate technical promise.
Clairity Breast’s NCCN Inclusion Highlights the Growing Power of AI Risk Stratification
Clairity Breast was added to NCCN guidance for breast cancer screening and diagnosis, a meaningful milestone for an AI product trying to become part of standard care. The development suggests guideline bodies are increasingly open to AI when it supports better risk-based screening. The move also illustrates how quickly breast imaging AI is transitioning from innovation story to clinical infrastructure story.
Breast Imaging AI Moves Into the Guideline Era as Clairity Breast Gets NCCN Recognition
Clairity Breast's addition to NCCN guidelines marks an important milestone for AI-based breast cancer risk assessment, signaling that artificial intelligence is beginning to influence standard screening pathways rather than sitting on the experimental fringe. The move could accelerate adoption of image-based risk stratification, especially for women who might otherwise be missed by traditional approaches.
Roswell Park’s NCCN Agenda Shows Where Cancer AI Is Becoming Operational, Not Experimental
Roswell Park’s upcoming presentations at the NCCN 2026 annual conference offer a window into the priorities now shaping cancer care innovation. Conference signals matter because they show where oncology AI and analytics are moving from isolated pilots toward guideline-adjacent, workflow-level use.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.